1h Free Analyst Time
According to the recently published report 'Plasminogen Activator Inhibitor 1 - Drugs In Development, 2022'; Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 15 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. Speak directly to the analyst to clarify any post sales queries you may have.
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis. PAI-1 is mainly produced by the endothelium and also by other tissue types, such as adipose tissue. PAI-1 inhibits the serine proteases tPA and urokinase and hence inhibit the physiological process that degrades blood clots. PAI-1 inhibits the activity of matrix metalloproteinases (important role in invasion of malignant cells across the basal lamina).
The report 'Plasminogen Activator Inhibitor 1 - Drugs In Development, 2022' outlays comprehensive information on the Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 7 molecules, respectively. Report covers products from therapy areas Cardiovascular, Gastrointestinal, Oncology, Genito Urinary System And Sex Hormones, Respiratory, Central Nervous System, Immunology, Infectious Disease, Genetic Disorders, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology and Undisclosed which include indications Arterial Thrombosis, Coronavirus Disease 2019 (COVID-19) Pneumonia, Idiopathic Pulmonary Fibrosis, Inflammatory Bowel Disease, Melanoma, Non Alcoholic Fatty Liver Disease (NAFLD), Renal Failure, Thrombosis, Acute Respiratory Distress Syndrome, Alpha-1 Antitrypsin Deficiency (A1AD), Beta Thalassaemia, Breast Cancer, Bronchiectasis, Central Nervous System (CNS) Tumor, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Emphysema, Fibrosis, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Head And Neck Cancer, Hepatocellular Carcinoma, Interstitial Lung Fibrosis, Metastatic Lung Cancer, Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), Multiple Sclerosis, Neuromyelitis Optica (Devic’s Syndrome), Non-Small Cell Lung Carcinoma, Obesity, Open-Angle Glaucoma, Pediatric Diffuse Intrinsic Pontine Glioma, Recurrent Glioblastoma Multiforme (GBM), Sickle Cell Disease, Small-Cell Lung Cancer, Solid Tumor, Stroke, Systemic Sclerosis (Scleroderma), Thromboembolism, Unspecified and Venous (Vein) Thrombosis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)
- The report reviews Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- REPORT COVERAGE
- Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Overview
- Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Companies Involved in Therapeutics Development
- Accendatech Co Ltd
- Advanced Vision Technologies (New York)
- Astellas Pharma Inc
- Beam Therapeutics Inc
- Jazz Pharmaceuticals Plc
- MDI Therapeutics Inc
- Second Genome Inc
- Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Drug Profiles
- ACT-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Alpha-1 Antitrypsin Deficiency - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AS-3288802 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Bi-specific Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke - Drug Profile
- Product Description
- Mechanism Of Action
- defibrotide sodium - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Gene Therapy to Inhibit SERPINE1 for Open-Angle Glaucoma - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MDI-2268 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MDI-2517 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
- Product Description
- Mechanism Of Action
- SG-500455 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SK-216 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TM-5275 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TM-5441 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TM-5484 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TM-5614 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Dormant Products
- Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Discontinued Products
- Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Product Development Milestones
- Featured News & Press Releases
- May 24, 2022: Second Genome presents new data at Digestive Disease Week (DDW) 2022 demonstrating that SG-5-00455, a potential first-in-class precision therapeutic, improves epithelial barrier function and promotes mucosal healing in inflammatory bowel disease
- Feb 24, 2022: Second Genome virtual KOL event highlighted critical role of mucosal healing and PAI-1/2 in Inflammatory Bowel Disease (IBD)
- Feb 18, 2022: Second genome presents new preclinical data for SG-5-00455, potential first-in-class development candidate targeting PAI-1/2 for the treatment of inflammatory bowel disease (IBD), at the 17th Congress of European Crohn's and Colitis Organization (ECCO)
- Feb 14, 2022: Second Genome to host virtual KOL event to discuss the role of mucosal healing and PAI-1/2 in inflammatory bowel disease on February 23
- Feb 10, 2022: Second Genome nominates development candidate targeting PAI-1/2 for the treatment of inflammatory bowel disease (IBD)
- Dec 02, 2021: ACT001 combined with PD-1 in the treatment of relapsed GBM completed the first subject dosing in the United States at MD Anderson
- Nov 18, 2021: Second Genome presents preclinical data at Crohn's & Colitis Foundation's IBD Innovate Conference for potential first in class mucosal healing therapeutic SG-5-00455
- Nov 08, 2021: China's original drug achieves "zero" breakthrough and is the first to be granted the rare disease qualification for children by the US FDA
- Jul 07, 2021: The new immunomodulator ACT001 shows great potential
- May 20, 2021: Jazz to present new data on Defitelio at EHA2021
- Nov 13, 2020: Beam Therapeutics presents first data highlighting Base Editing Program for Alpha-1 Antitrypsin Deficiency at AASLD
- Jul 31, 2020: Clinigen receives regulatory approval for Defitelio (Defibrotide) in Australia
- May 14, 2020: Jazz Pharmaceuticals announces presentation on Defitelio at Virtual EHA 2020 Meeting
- Apr 29, 2020: Jazz Pharmaceuticals stops enrollment in phase 3 study evaluating Defibrotide for the prevention of Veno-Occlusive Disease
- Apr 28, 2020: Beam Therapeutics to present first data highlighting base editing program for alpha-1 antitrypsin deficiency at 23rd ASGCT Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Accendatech Co Ltd, 2022
- Pipeline by Advanced Vision Technologies (New York), 2022
- Pipeline by Astellas Pharma Inc, 2022
- Pipeline by Beam Therapeutics Inc, 2022
- Pipeline by Jazz Pharmaceuticals Plc, 2022
- Pipeline by MDI Therapeutics Inc, 2022
- Pipeline by Second Genome Inc, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Accendatech Co Ltd
- Advanced Vision Technologies (New York)
- Astellas Pharma Inc
- Beam Therapeutics Inc
- Jazz Pharmaceuticals Plc
- MDI Therapeutics Inc
- Second Genome Inc
